• See the Final Highlights of the ISTH 2015 Scientific Program

    The ISTH 2015 Congress featured an outstanding array of scientific presentations, and since our last email update, we have uploaded several new articles from the sessions on Wednesday and Thursday. See below for links to those articles:
    Meaningful Genetic Testing for Thrombophilia is Tantalizingly Close (Article and Video)
    RNA Subpopulations Targeted for Control of Cardiovascular Disease
    Earlier Start …

    READ MORE
  • RNA Subpopulations Targeted for Control of Cardiovascular Disease

    Several non-coding RNA subpopulations show promise as therapeutic targets in the control of cardiovascular disease, according to Stefanie Dimmeler, who delivered the Louis B. Jaques Plenary Lecture at the ISTH 2015 Congress Thursday.
    A small number of phase II trials in this area have been completed, with more clinical trials anticipated. The real excitement about non-coding …

    READ MORE
  • Observational Study Offering Real-Life Insights into the Burden and Mortality of Venous Thromboembolism (VTE) in Patients with Active Cancer Presented at ISTH 2015

    New real-life evidence from a UK observational study, presented at ISTH 2015, reveals the burden and mortality of venous thromboembolism (VTE) in patients with active cancer over a 10 year period1,3. Key findings from the study underscore the need for improved blood clot management in these patients:

     VTE is common in patients with active cancer: During …

    READ MORE
  • State of the Art Session Addresses Controversies in Antiplatelet Therapy for Patients with CAD

    Antiplatelet drugs should prevent secondary ischemic events and should be safe for long-term use – without incurring an unacceptable increase in bleeding risk. This goal remains elusive, as mortality and morbidity remain high in coronary artery disease (CAD).
    On Wednesday morning, three experts came together during a State of the Art session at the ISTH 2015 …

    READ MORE
  • Topics on Anticoagulant-Associated Bleeding Take Center Stage

    Millions of patients take vitamin K antagonists (VKA) for the treatment and prevention of thromboembolic events, but 1-3% of patients who take them have life-threatening or fatal bleeds. Up to 2% suffer intracranial hemorrhage, which results in death in up to 79% of cases.
    “There are more than 42,000 [hospital] admissions related to serious bleeds with …

    READ MORE
  • Meaningful Genetic Testing for Thrombophilia is Tantalizingly Close

    Multiple strategies for examining genetic determinants of thrombosis are likely to explain clotting events mediated by a complex set of interactions that includes multiple genes and environmental factors, according to David Ginsburg, who delivered Wednesday’s Michael E. Nesheim Plenary Lecture.
    This progress is important, he said, because none of the genes associated with blood clotting disorders …

    READ MORE
  • Earlier Start to Plasma Transfusions for Persistent Postpartum Hemorrhage Does Not Improve Maternal Outcomes

    For women with persistent postpartum hemorrhage, correction of coagulopathy by administering plasma is often an inevitable treatment decision. There are little clinical data, however, on whether an early or a late start for plasma transfusion leads to more positive maternal outcomes.
    Data presented on Wednesday at the ISTH 2015 Congress by Dacia Henriquez of the Department …

    READ MORE
  • Gene Therapy Trial Takes Aim at Hemophilia B

    Researchers may be making some headway in the search for a gene therapy strategy to treat hemophilia B.
    Preliminary findings from an ongoing phase 1-2 trial of an investigational gene therapy treatment to address clotting and immune response in patients with hemophilia B were presented Wednesday at the ISTH 2015 Congress.
    Previous research efforts to use gene …

    READ MORE
  • State of the Art: Intrinsic Coagulation Pathway May Yield Therapeutic Targets

    Major strides have been made in understanding the intrinsic coagulation pathway, producing potential new targets for therapies designed to prevent thrombus formation, according to a three-part State of the Art session held Tuesday at the ISTH 2015 Congress. Thrombi induced by medical devices are among the potential targets of effective inhibitors of the intrinsic coagulation …

    READ MORE
  • State of the Art: Longer-acting clotting factor concentrates

    Tuesday morning’s State of the Art session on “longer-acting clotting factor concentrates” highlighted recent advances in therapeutics for hemophilia, with a focus on existing and evolving approaches to treatment. Jerry S. Powell, medical director, coagulation, for CSL Behring, discussed, among other topics,  a factor VIII (FVIII) fusion protein. Andreas Tiede of Hannover Medical School, Germany, …

    READ MORE
  • Why We Miss the Mark on Preventing Cardiovascular Disease

    If you don’t think clinicians should be worried about the current state of cardiovascular disease (CVD) prevention, consider data from the 2011 World Health Organization Global Atlas on CVD Prevention and Control. It found that worldwide, CVD accounts for 31% of deaths: 17.5 million in 2012, projected to increase to 23.3 million in 2030.
    At the …

    READ MORE
  • Advances in Imaging are Helping Researchers Better Understand Immunity

    For more than two decades, Paul Kubes has been studying ways to directly visualize the role of immune cells during inflammation, infection and tissue injury, both in vitro and in vivo.
    During the Tuesday morning J. Fraser Mustard Plenary Lecture at the ISTH 2015 Congress, he discussed several examples of how cutting-edge technologies, such as spinning-disk …

    READ MORE
  • Study Establishes Protocol for Perioperative Discontinuation of Dabigatran 

    In atrial fibrillation (AF) patients who must discontinue dabigatran for elective surgery, the risk of both stroke and major bleeding can be reduced to very low levels using a formalized strategy for stopping and then re-starting anticoagulation, according to results of a prospective study.
    Among key findings presented at a press conference at the ISTH 2015 …

    READ MORE
  • State of the Art: Platelet Function and Dysfunction

    Three world-renowned speakers – Alan Nurden of France, Marco Cattaneo of Italy, and Barry Coller of the Unites States – came together Monday to present the state of the art regarding platelet function and dysfunction during a session named for 1981 ISTH Congress President  J. Fraser Mustard, who was a pioneer in the area of …

    READ MORE
  • Leader in Cardiovascular Medicine Thanks ISTH in Schofield Plenary Lecture

    In the Frank Schofield Plenary Lecture on Monday morning, Eugene Braunwald, Brigham and Women’s Hospital, Harvard Medical School, Boston, first thanked the members of ISTH for what they have achieved so far in controlling thrombosis and then asked for more.
    “We want you to give us greater improvement in the efficacy-bleeding relationship,” Braunwald said at the …

    READ MORE
  • Nurses Forum Provides Education, Networking Opportunities for Nurses and Allied Health Professionals

    More than 150 nurses participated in the two-day Nurses Forum, which was held Sunday and Monday at the ISTH 2015 Congress.
    Maura Malone
    The Nurses Forum is a special session that was launched at the ISTH 2005 Congress in Sydney, Australia. Its goal is to provide nurses and allied health professionals, from around the world, with an …

    READ MORE
  • Idarucizumab Reverses Dabigatran’s Anticoagulant Effects

    Idarucizumab is a promising agent that quickly and safely reverses the anticoagulant effects of dabigatran whether the goal is to control serious bleeding or to permit urgent surgery, according to interim results of a multicenter trial presented Monday by Charles Pollack, chair of the department of emergency medicine at Pennsylvania Hospital in Philadelphia.
    Charles Pollack
    Idarucizumab is …

    READ MORE
  • Routine Screening Sufficient for Detecting Occult Cancer in Patients with VTE

    The prevalence of occult cancer is low in patients with a first unprovoked venous thromboembolism, according to results from a multicenter, randomized study presented at the ISTH 2015 Congress.
    In addition, routine screening with the addition of a comprehensive computed tomography (CT) scan of the abdomen and pelvis was no better than routine screening alone in …

    READ MORE
  • Risk of Major Bleeding is Decreased When AF Patients Do Not Receive Bridging Anticoagulation

    Forgoing bridging anticoagulation in patients with atrial fibrillation (AF) is non-inferior to perioperative bridging with low-molecular weight heparin for the prevention of arterial thromboembolism and decreases the risk of major bleeding, according to results presented at the meeting Monday and published simultaneously in the New England Journal of Medicine.
    Study investigator Thomas Ortel, chief of the …

    READ MORE
  • Nigel Key: Practice-changing Trial Results on Tap this Week

    In an interview, Nigel Key, the ISTH Council Chair, identified several trials being presented this week that are likely to be practice changing. This includes two late-breaking abstracts presented Monday that will be simultaneously published in the New England Journal of Medicine. Release of this data at the 2015 ISTH Congress is appropriate. Key explained …

    READ MORE
  • SSC Chair Reflects on Wide-Ranging Sessions

    The Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis met on the front end of the ISTH 2015 Congress, with no shortage of topics discussed.
    For example, attendees of the session on women’s issues learned about the formation of a registry that’s tracking women who are taking new oral anticoagulants during …

    READ MORE